Evaluation of Dapagliflozin Taken Twice-daily

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

Also called NCT01217892

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01217892
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany, Hungary, Romania, Slovakia, South Africa, Switzerland, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01217892. Randomized; quadruple masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2013-11-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Dapagliflozin Taken Twice-daily
Intervention (Drug)
dapagliflozin
Intervention (Drug)
dapagliflozin
Intervention (Drug)
dapagliflozin
Intervention (Drug)
metformin
Intervention (Drug)
placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01217892
Content hash
cb80846f63aa2443497d65b11589ecd9979fd331e580f53ca424fe3b5fc1f4f8